CCM
FPRX

Cupps Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Cupps Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.54M Sell
29,387
-6,563
-18% -$313K 0.67% 61
2016
Q2 		$1.49M Sell
35,950
-300
-0.8% -$13K 0.38% 98
2016
Q1 		$1.47M Buy
+36,250
New +$1.25M 0.28% 105

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cupps Capital Management's FPRX Position: Q3 2016 in Review

Cupps Capital Management reduced its Five Prime Therapeutics, Inc. (FPRX) stake by 18% in Q3 2016, selling an estimated $313K and leaving 29,387 shares worth $1.54M. The position accounts for 0.67% of the portfolio, ranked #61.

Cupps Capital Management first reported a position in FPRX in Q1 2016 and has held it in 3 quarters since. 177 funds tracked by Wall St. Rank hold FPRX as of Q3 2016.

  • Cupps Capital Management held 29,387 shares of Five Prime Therapeutics, Inc. worth $1.54M as of Q3 2016.
  • Cupps Capital Management sold 6,563 Five Prime Therapeutics, Inc. shares in Q3 2016, an estimated $313K.
  • Five Prime Therapeutics, Inc. made up 0.67% of Cupps Capital Management's portfolio in Q3 2016, its #61 holding.
  • Cupps Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and has held it in 3 quarters since.
  • 177 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.